Analysts expect that United Therapeutics Co. (NASDAQ:UTHR) will report sales of $372.32 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for United Therapeutics’ earnings. The highest sales estimate is $412.00 million and the lowest is $332.50 million. United Therapeutics posted sales of $445.50 million during the same quarter last year, which suggests a negative year-over-year growth rate of 16.4%. The business is expected to issue its next earnings report on Wednesday, October 24th.
According to Zacks, analysts expect that United Therapeutics will report full-year sales of $1.53 billion for the current year, with estimates ranging from $1.45 billion to $1.60 billion. For the next financial year, analysts forecast that the company will post sales of $1.22 billion, with estimates ranging from $1.11 billion to $1.42 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $1.41. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The firm had revenue of $444.50 million for the quarter, compared to the consensus estimate of $368.63 million. During the same quarter in the prior year, the business earned $4.37 earnings per share. The company’s revenue was up .0% compared to the same quarter last year.
Shares of UTHR traded down $2.88 during mid-day trading on Wednesday, reaching $122.95. The company had a trading volume of 317,191 shares, compared to its average volume of 327,836. United Therapeutics has a 52-week low of $100.57 and a 52-week high of $152.55. The company has a quick ratio of 4.35, a current ratio of 4.64 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $5.48 billion, a price-to-earnings ratio of 11.29, a PEG ratio of 28.40 and a beta of 1.21.
In other United Therapeutics news, Director Richard Giltner sold 3,240 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 810 shares of the stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $119.00, for a total value of $96,390.00. Following the transaction, the director now owns 1,555 shares in the company, valued at approximately $185,045. The disclosure for this sale can be found here. Insiders have sold 4,860 shares of company stock worth $611,161 in the last quarter. 8.20% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. Legacy Financial Advisors Inc. purchased a new position in United Therapeutics during the second quarter worth approximately $107,000. Sun Life Financial INC purchased a new position in United Therapeutics during the second quarter worth approximately $198,000. Fox Run Management L.L.C. purchased a new position in United Therapeutics during the second quarter worth approximately $269,000. HL Financial Services LLC boosted its position in United Therapeutics by 32.1% during the second quarter. HL Financial Services LLC now owns 2,711 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 658 shares in the last quarter. Finally, Worldquant Millennium Quantitative Strategies LLC purchased a new position in United Therapeutics during the second quarter worth approximately $347,000. Institutional investors own 95.67% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Story: Rule of 72
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.